This hexapeptide acts as a sterolregulated ER sorting signal. These studies define the biochemical parameters responsible for regulated sorting of an ER membrane protein into COPII coated vesicles.
In mammalian cells the synthesis of cholesterol and other lipids is governed by the lateral movement of a membrane-embedded protein complex into coated vesicles that bud from the endoplasmic reticulum (ER) and move to the Golgi. This membrane sorting event is blocked selectively by cholesterol and related oxysterols, and it constitutes the only known instance in which ER-to-Golgi transport of a protein is regulated selectively by a small molecule (1, 2) . An understanding of this regulatory mechanism is therefore essential to a general understanding of regulated ER-to-Golgi transport as well as to an understanding of lipid metabolism.
The crucial components of the sterolregulated protein complex are sterol regulatory element-binding proteins (SREBPs), which are membrane-embedded transcription factors that are synthesized on ER membranes (3) . SREBPs are anchored to ER membranes by virtue of two transmembrane helices. In order to activate lipid synthesis, the SREBPs must be transported to the Golgi where proteases release the active domains that enter the nucleus. ER-to-Golgi transport requires that the SREBPs form complexes with Scap, an escort protein that contains eight membrane-spanning helices (4) . In sterol-depleted cells, the Scap/SREBP complex clusters laterally with other proteins into COPII coated vesicles that bud from the ER (5) . Like other proteins that cluster into COPII coated vesicles (6) , clustering of the Scap/SREBP complex is initiated by Sar1, a small GTPase that binds to ER membranes in a GTP-dependent fashion (2) . Sar1 recruits a heterodimeric protein called Sec23/24, and this recruits another heterodimer, Sec13/31, which forms the coat of the COPII coated vesicle, thereby permitting vesicle budding. Using in vitro binding assays with purified COPII components, Espenshade, et al. (2) demonstrated that Sec23/24 binds to the Scap/SREBP complex in a fashion dependent upon Sar1-GTP. This binding did not occur when membranes were isolated from intact cells that were preincubated with sterols, a condition in which the Scap/SREBP complex does not move to the Golgi (5) .
To gain a molecular understanding of the mechanism by which sterols block the binding of COPII proteins to the Scap/SREBP complex, it is necessary to establish an in vitro system in which binding can be blocked by addition of sterols to isolated membranes, rather than to preincubated cells. The feasibility of such an assay is increased by the recognition that sterol-mediated inhibition of Scap/SREBP transport requires Insigs, which are resident proteins of the ER that have an anchor function. Addition of sterols to intact cells or to isolated membranes triggers the binding of Scap to Insigs, an event that is required for sterol-mediated inhibition of Scap/SREBP transport (7) . The Insig requirement was first evident when the membrane domain of Scap was overexpressed in cells by transfection.
Under these conditions the endogenous Insigs became saturated, and sterols no longer blocked ER-to-Golgi transport (7, 8) . This deficiency was overcome by overexpression of Insig-1 or Insig-2 (7, 9) . The Insig requirement was confirmed when Insig-deficient mutant CHO cells were shown to be resistant to sterol-mediated inhibition of Scap/SREBP transport (10) .
In the current studies, we demonstrate that sterols can block the Sar1-dependent binding of COPII proteins to the Scap/SREBP complex when added to isolated membranes in vitro and that this inhibition requires Insigs. Through mutagenesis studies, we identify a hexapeptide sequence (MELADL) in a cytoplasmic loop of Scap that is required for COPII binding in vitro and for ER-toGolgi movement of the Scap/SREBP complex in intact cells. These studies demonstrate that cell membranes contain all of the components required for sterol-mediated regulation of Scap/SREBP transport and thereby for transcriptional regulation of lipid synthesis in animal cells.
EXPERIMENTAL PROCEDURES
Reagents -We obtained Glutathione-Sepharose 4 Fast Flow beads from Amersham; FuGENE 6, GTP, GMP-PNP, and creatine phosphokinase from Roche Diagnostics; ATP and creatine phosphate from Sigma; digitonin and NP-40 from Calbiochem; methyl-β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin from Cyclodextrin Technologies Development Inc.; and Protein A/G beads from Santa Cruz. Solutions of sodium mevalonate and compactin were prepared as described (11, 12) . Newborn calf lipoproteindeficient serum (d > 1.25 g/ml) was prepared by ultracentrifugation (13) . Antibodies -We obtained monoclonal anti-T7 IgG (Cat. No. 69522-4) and anti-HSV IgG (69171-4) from Novagen; monoclonal anti-Flag IgG (F3165) from Sigma; monoclonal anti-GST IgG (SC-138) from Santa Cruz; and polyclonal anti-Myc IgG (A190-205A) and polyclonal anti-T7 IgG (A190-117A) from Bethyl Laboratories. The following antibodies were previously described in the indicated reference: polyclonal IgG-R139 against hamster Scap (amino acids 54-277 and 540-707) (4), monoclonal IgG-9D5 against hamster Scap (amino acids 540-707) (4), monoclonal IgG-ID2 against human SREBP-2 (amino acids 48-403) (9) , and monoclonal IgG-9E10 against Myc (9) . Expression Plasmids -The following plasmids were described in the indicated reference: pCMVInsig-1-Myc, which encodes amino acids 1-277 of human Insig-1 followed by six tandem copies of a Myc tag under control of the cytomegalovirus (CMV) promoter (7); pTK-HSV-BP2, which encodes full-length human SREBP-2 with an HSV tag at its NH 2 -terminus under control of the thymidine kinase (TK) promoter (4); pCMV-Scap, which encodes the open reading frame of hamster Scap (1); pCMV-VSVG-T7, which encodes amino acids 1-512 of VSV G protein from the ts045 mutant strain of vesicular stomatitis virus followed by two copies of a T7 tag under control of the CMV promoter (1).
The following plasmids were constructed by standard methods (14) : pACMV-Scap(1-448)-Myc and pACMV-Scap(1-464)-Myc, which encode hamster Scap (amino acids 1-448 and 1-464, respectively) followed by six tandem copies of a Myc tag under control of the CMV promoter, and pACMV-Scap(504-1276), which encodes hamster Scap (amino acids 504-1276), were constructed with pACMV-tetO (15) as the parent vector. pCMV-Scap(1-448)-Myc, pCMV-Scap(1-541)-Myc, and pCMV-Scap(1-1276)-Myc, which encode hamster Scap (amino acids 1-448, 1-541, and 1-1276, respectively) followed by six tandem copies of a Myc tag under control of the CMV promoter, and pCMV-Scap(1-767), which encodes hamster Scap (amino acids 1-767), were constructed with pCMV-Scap as the parent vector. pCMV-Insig-1-T7, which encodes full-length human Insig-1 (amino acids 1-277) followed by three tandem copies of the T7-epitope tag (MASMTGGQQMG), was constructed with pcDNA3 as the parent vector.
Mutant versions of pCMV-Scap were generated with the QuickChange II XL SiteDirected Mutagenesis Kit (Stratagene). All plasmids were fully sequenced. Culture Medium -Medium A contains a 1:1 mixture of Ham's F-12 and Dulbecco's modified Eagle medium supplemented with 100 µg/ml of streptomycin sulfate and 100 units/ml of penicillin.
Sterol-depleting Medium contains medium A supplemented with 5% newborn calf lipoprotein-deficient serum, 50 µM sodium mevalonate, and 50 µM compactin. Medium B contains HyQ SFX-MAb complete serum-free medium supplemented with 10% FCS, 10 mM Lglutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate. Cell Culture and Transfection -SRD-13A cells, a Scap-deficient cell line derived from Chinese hamster ovary (CHO)-7 cells (16), were grown in monolayer at 37°C in 8-9% CO 2 in medium A supplemented with 5% (v/v) fetal calf serum (FCS), 1 mM sodium mevalonate, 20 mM sodium oleate, and 5 µg/ml cholesterol. On day 0, cells were set up for experiments in 10 ml of the above medium at a density of 7 x 10 5 cells per 100-mm dish. On day 2, cells were transfected with various plasmids (described in Figure legends ) in 8 ml of medium A supplemented with 5% FCS using FuGENE 6 as a transfection agent (16) . For each transfection, the total amount of DNA was adjusted to 3 µg/dish by addition of pcDNA3 mock vector. Twelve h later, the cells were treated with 1% (w/v) hydroxypropyl-β-cyclodextrin for 1 h in 8 ml of sterol-depleting medium. Cells were then washed twice with phosphate-buffered saline and refed with 8 ml of sterol-depleting medium for 3-3.5 h prior to harvest for use in the assays described below. Recombinant Proteins -Recombinant hamster GST-Sar1 and GST-Sar1(H79G) were produced in E. coli Bl21 as GST fusion proteins (2) . Recombinant Flag-Sec23/His-Sec24 is a heterodimeric complex of mouse Sec23A tagged with two Flag tags (DYKDDDDK) and human Sec24C tagged with a 6XHis tag (2) . These proteins were co-expressed in Sf9 insect cells, and the heterodimer was purified by nickel chromatography as previously described (2) with minor modifications.
GST-Sar1 and FlagSec23/His-Sec24 were each passed through a PD-10 column equilibrated with buffer A (50 mM Hepes-KOH at pH 7.2, 250 mM sorbitol, 70 mM potassium acetate, 5 mM sodium EGTA, 1.5 mM magnesium acetate) supplemented with 1 mM dithiothreitol and protease inhibitor cocktail (10 µg/ml leupeptin, 10 µg/ml pepstatin A, 6 µg/ml aprotinin, and 25 µg/ml N-acetyl-leucinal-leucinalnorleucinal (ALLN)). All purified proteins were frozen quickly in liquid nitrogen and stored at -80°C for up to 2 months without loss of activity.
Preparation of Hamster Microsomal Membranes -
Microsomal membranes from SRD-13A cells were isolated as previously described (1) (2) with several minor modifications. Each reaction, in a final volume of 150 µl of buffer A, contained 80-160 µg microsomal membrane protein, 50 µg bovine serum albumin, 10 µg recombinant GSTSar1, 10 µg recombinant Sec23/24 complex, 1.5 mM ATP, 0.5 mM GTP, 10 mM creatine phosphate, 4 units/ml creatine kinase, and protease inhibitor cocktail. Reactions were conducted at 28°C for 15 min. Membranes were collected by sedimentation (4°C, 20,000g for 5 min). The pellet was resuspended in 0.3 ml of buffer C (50 mM Hepes-KOH at pH 7.2, 2.5 mg/ml bovine serum albumin, 150 mM KCl, 1 mM MgCl 2 , and protease inhibitor cocktail) and solubilized with 0.5% (w/v) digitonin at 4°C for 30 min. After centrifugation at 20,000g for 10 min at 4°C, the supernatant was incubated with GlutathioneSepharose beads at 4°C for 30 min to pull down GST-Sar1.
The beads were pelleted by centrifugation. A 30-µl aliquot of the supernatant was combined with 10 µl of 5X SDS sample buffer and subjected to SDS-8% PAGE and immunoblotting. The pelleted bead fraction was washed three times with buffer C, after which proteins were eluted by incubation with 100 µl of 2X SDS loading buffer at 37°C for 30 min, followed by centrifugation. An aliquot of the resulting supernatant was subjected to SDS-PAGE and immunoblotting for Scap or Insig-1. Preparation of Human HEK-293S CytosolHuman HEK-293S cells (15) were grown in suspension for 6 days in medium B at 37°C without CO 2 (7) . After the cells were harvested, the cell pellets were frozen in liquid nitrogen and stored at -80°C. Before use, a cell pellet from 1 liter of cells was thawed on ice and then douncehomogenized 40 times in 30 ml of cold buffer A supplemented with 1 mM dithiothreitol and protease inhibitor cocktail. All subsequent steps were carried out at 4°C. The cell homogenate was centrifuged at 1,000g for 10 min, after which the supernatant was centrifuged at 20,000g for 20 min and then twice at 180,000g for 30 min. In collecting the supernatant after each spin, care was taken to avoid the fat layer. The final supernatant, designated as cytosol, was divided into multiple aliquots (each containing 5-10 mg protein/ml), frozen in liquid nitrogen, and stored at -80°C. In Vitro Vesicle Budding Assay -The protocol was adapted from procedures originally described by the laboratories of Schekman (17) and Balch (18) and modified as described previously (1, 2) . Each reaction contained, in a final volume of 80 µl of buffer A, 40-80 µg microsomal membranes from SRD-13 cells, 150-300 µg of human HEK-293S cytosol, 1.5 mM ATP, 0.5 mM GTP, 10 mM creatine phosphate, 4 units/ml creatine kinase, and protease inhibitor cocktail. After incubation for 15 min at 28°C, the membrane fraction (16,000g pellet) and the vesicle fraction (16,000g supernatant) were separated by centrifugation and subjected to SDS-8% PAGE and immunoblot analysis as previously described (1). Immunoprecipitation -The cell pellets from two 100-mm dishes of transfected SRD-13A cells were combined, resuspended in 1 ml of 0.1% (w/v) NP-40 in buffer C, and passed through a 22-gauge needle eight times, followed by incubation for 1 h at 4ºC.
After the lysate was cleared by centrifugation at 100,000g for 20 min, the supernatant was subjected to immunoprecipitation as described (7), except that the concentration of rabbit polyclonal anti-Myc IgG and anti-T7 IgG were 10 and 5 µg/ml, respectively. Immunoblot Analysis -SDS-8% PAGE gels were calibrated with molecular weight markers (Invitrogen), and primary antibodies were used at the following concentrations: polyclonal anti-Scap IgG-R139, 5 µg/ml; monoclonal anti-Scap IgG-9D5, 5 µg/ml; monoclonal anti-SREBP-2 IgG-1D2, 5 µg/ml; monoclonal IgG-HSV, 67 ng/ml; monoclonal IgG-T7, 0.5 µg/ml; and monoclonal anti-Myc IgG-9E10, 2 µg/ml. Two secondary antibodies (horseradish peroxidase-conjugated, affinity purified donkey anti-mouse IgG and antirabbit IgG (Jackson ImmunoResearch)) were each used at a dilution of 1:5000. Bound antibodies were visualized by chemiluminescence using the Supersignal Substrate System (Pierce) and exposed to Kodak X-Omat Blue XB-1 film (NEN) at room temperature for 1-120 s.
RESULTS
Fig . 1A illustrates the previously demonstrated complex between Scap and the COPII proteins, Sec23/24 (2) . Formation of this complex is initiated by Sar1 in the GTP-bound form. Binding of Sar1 to Scap requires the Sec23/24 complex (2). In the current study, we used the GST-Sar1 pulldown assay that was used by Espenshade, et al. (2) . Scap-deficient CHO cells (SRD-13A cells) were transfected with plasmids encoding epitope-tagged versions of Scap, SREBP-2, and Insig-1.
Cells were incubated in sterol-depleting medium containing hydroxypropyl-β-cyclodextrin to remove sterols. Some of the dishes received 25-hydroxycholesterol to replenish sterols. After 4 h, the cells were harvested, and microsomal membranes were incubated in vitro with a solution containing recombinant mammalian wild-type or mutant GST-tagged Sar1 and Flag-tagged Sec23/24 (see Fig. 1A ). After incubation for 15 min, the membranes were solubilized with detergent, incubated with Glutathione-Sepharose beads, and pelleted as described under "Experimental Procedures." The pelleted proteins were subjected to SDS-PAGE and blotted with antibodies to Scap or to the tags on Sar1 or Sec23. All of the GST-Sar1 was found in the pellet fraction, indicating complete trapping of the GSTSar1 on the glutathione beads (Fig. 1B, bottom  panel) . When wild-type GST-Sar1 was used, a fraction of Sec23 was co-pelleted when the incubations were performed in the presence of nonhydrolyzable GMP-PNP (middle panel, lanes 3 and 4), but not in the presence of GTP (lanes 1 and 2). This finding is consistent with previous data showing that the Scap/COPII complex is disrupted by GTP hydrolysis (2) . Pre-incubation of the cells with 25-hydroxycholesterol had no effect on the GST-Sar1 pulldown of Sec23, indicating that binding of Sar1 to Sec23/24 is not regulated by sterols. In the presence of GMP-PNP, Scap was co-pelleted with the Sar1-Sec23/24 complex (top panel, lane 3), but this did not occur when the cells were incubated with 25-hydroxycholesterol (lane 4). When the GTPase-defective H79G mutant of Sar1 was used, Sec23 and Scap were coprecipitated in the presence of either GTP or GMP-PNP (lanes 5-8) . Again, preincubation of cells with 25-hydroxycholesterol prevented the binding of Scap to the Sar1-Sec23/24 complex. These findings replicate the previously published results of Espenshade, et al. (2) .
In cultured cells, the sterol-mediated inhibition of Scap exit from the ER requires Insig proteins (8) . When Scap is overexpressed by transfection of a cDNA driven by the strong CMV promoter, endogenous Insigs become saturated and sterols fail to inhibit Scap exit unless Insig protein is also overexpressed by transfection (8) .
To determine whether the sterol-mediated inhibition of COPII binding to Scap also requires Insig, we performed the GST-Sar1 pulldown assay in cells that overexpressed Scap alone or Scap plus two different amounts of Insig-1 ( Fig. 2A) . In the absence of Insig-1 co-expression, incubation with sterols did not prevent Scap binding to the COPII complex (upper panel, lanes 1 and 2) . Coexpression of either amount of Insig-1 restored sterol-dependent inhibition of this binding (lanes 3-6). Insig-1 was never co-precipitated with the COPII complex ( Fig. 2A, lower panel) , a finding consistent with the previous observation that Insig proteins do not leave the ER (8, 9) . The Y298C mutant of Scap shows a markedly reduced binding affinity for Insigs (8, 9) , and it moves to the Golgi even in the presence of 25-hydroxycholesterol (5). Consistent with these findings, Scap(Y298C) continued to bind to COPII proteins even in cells that expressed Insig-1 and were treated with 25-hydroxycholesterol (Fig. 2B, lanes 4-6) . In the same experiment, 25-hydroxycholesterol abolished binding of COPII proteins to wild-type Scap (lanes 1-3) .
We next sought to determine whether sterols would inhibit Scap binding to COPII proteins when added directly to microsomal membranes in vitro rather than to the intact cells before harvest (Fig. 3) . As a control for these experiments, we transfected cells with a plasmid encoding VSV G protein, a transmembrane viral protein that exits the ER by binding to COPII proteins (19) . When membranes were prepared from cells overexpressing Scap in the absence of Insig-1, Scap was co-pelleted with GST-Sar1, and sterols did not inhibit this binding when added in vitro, either in ethanol or in the presence of methyl-β-cyclodextrin as a carrier (Fig. 3, upper  panel, lanes 1-6) . Similar results were observed with VSV G protein (lower panel, lanes [1] [2] [3] [4] [5] [6] . When the cells overexpressed Insig-1, the in vitro addition of 25-hydroxycholesterol at 5 or 20 µM in ethanol abolished GST-Sar1 binding to Scap, but not VSV G (lanes 9 and 10).
19-Hydroxycholesterol, which does not block movement of the Scap/SREBP complex to the Golgi, did not block the GST-Sar1 interaction with Scap, even when added at 20 µM (lane 8). Cholesterol at 2 µM selectively blocked binding of GST-Sar1 to Scap but not to VSV G (lane 12). Because of its poor solubility in ethanol/water mixtures, the cholesterol was added as a complex with methyl-β-cyclodextrin as a carrier.
To determine the region of Scap responsible for binding COPII proteins, we conducted mutagenesis studies. Fig. 4 shows the membrane-spanning domain of Scap with emphasis on the 78-amino acid cytoplasmic loop between transmembrane helices 6 and 7. For discussion purposes, we refer to this loop as loop 6. This is the longest of three loops on the cytoplasmic surface of Scap, the two others containing 9 and 30 amino acids. To explore the function of this loop, we prepared plasmids encoding Scap with termination codons at various positions and transfected them into Scap-deficient SRD-13A cells. Scap (1-448) lacks loop 6, whereas Scap(1-541) contains the full loop plus the subsequent membrane-spanning helix (Fig. 4) . Both forms of Scap were stable when expressed in SRD-13A cells, and both bound to Insig-1 in a sterol-dependent fashion as determined by coimmunoprecipitation with epitope-tagged Insig-1 (Fig. 5A, lanes 1-4) . In both cases the amount of co-immunoprecipitation was similar to that observed with full-length Scap(1-1276) (lanes [5] [6] . These data indicate that loop 6 is not required for sterol induction of Scap binding to Insig-1.
To determine whether loop 6 is required for Scap binding to COPII proteins, we expressed the truncated proteins, isolated membranes, and performed the GST-Sar1 pulldown assay (Fig.  5B) . In the absence of Insig-1, transfected Scap(1-541) and Scap(1-1276) were both pulled down with GST-Sar1, and 25-hydroxycholesterol did not inhibit this reaction (Fig. 5B, lanes 5, 6 and 9, 10 ). When Insig-1 was co-expressed, 25-hydroxycholesterol inhibited the interaction of both forms of Scap with Insig-1 (lanes 7, 8 and 11, 12) . On the other hand, Scap(1-448) was not pulled down by GST-Sar1 under any condition (lanes1-4). These data indicate that loop 6 is required for Scap to interact with the COPII protein complex.
To determine which part of loop 6 is required for the Sar1 interaction, we truncated the protein at position 464, leaving the first 24 amino acids of the loop intact. To test the function of this protein, we co-transfected a plasmid encoding it together with a plasmid encoding transmembrane helices 7 and 8 plus the entire COOH-terminus of Scap (designated Scap(504-1276) in Fig. 5C ). Previous studies showed that when a cDNA encoding the NH 2 -terminal half of Scap is cotransfected with a cDNA encoding the COOH-terminal half of Scap, the two halves of Scap reconstitute a functional molecule, thereby allowing sterol-regulated transport of SREBPs from ER to Golgi (8) . Thus, when Scap(1-464) was co-expressed with Scap(504-1276), the processing of SREBP-2 was restored, as reflected by an increase in nuclear SREBP-2 (Fig. 5C,  lanes 6-8) . Scap(1-448) was much weaker in this regard (lanes 2-5) . These data suggest that sequences within the first 24 amino acids in loop 6 of Scap are required for COPII binding and transport to the Golgi.
To localize the sequences within loop 6 that are required for COPII binding, we made a series of substitution mutations in pairs of residues in this loop (Fig. 6A) . We introduced the mutant plasmids into SRD-13A cells by transfection together with a plasmid encoding epitope-tagged SREBP-2, and measured the amount of the nuclear fragment of SREBP-2 by immunoblotting (Fig.  6B ). These data showed that mutations 4, 5, and 6 each led to a profound reduction in SREBP-2 processing.
These mutations disrupted a hexapeptide sequence, MELADL, which begins at position 447 (see Fig. 4 ) and lies within the critical region that was previously defined by the truncation mutations (Fig. 6A) . None of the other substitutions within loop 6 abolished SREBP-2 processing. Mutations 4, 5, and 6 also impaired the ability of Scap to bind to COPII proteins as determined by the GST-Sar1 pulldown assay in vitro (Fig. 6C) . Mutation 3, which disrupts the diarginine sequence adjacent to the hexapeptide, also lowered Scap binding to COPII proteins (Fig.  6C ), but this mutation did not abolish SREBP-2 processing in intact cells (Fig. 6B) . It is possible that the decrease revealed by the GST-Sar1 pulldown assay reflects a reduced affinity of this mutant protein for GST-Sar1 under the artificial conditions of the in vitro assay, but that the amount of Sar1 within the cell is sufficient to overcome this affinity problem, thereby permitting exit of the Scap-SREBP-2 complex from the ER.
To further explore the properties of the loop 6 mutants of Scap, we tested the ability of one of these mutants (number 6 -Scap(D451A;L452A)) to bind to Insig-1 in a sterol-dependent fashion (Fig. 7A) . SRD-13A cells were transfected with plasmids encoding wild-type or mutant Scap, epitope-tagged Insig-1, and SREBP-2. When the cells were preincubated with 25-hydroxycholesterol, both wild-type Scap and mutant 6 were co-immunoprecipitated with Insig-1. The immunoprecipitate also contained SREBP-2, indicating that Scap mutant 6 binds both Insig-1 and SREBP-2. Binding of Scap mutant 6 to Insig-1 was regulated by 25-hydroxycholesterol, indicating that this mutant retains the ability to undergo sterol regulation. The inability to bind to COPII proteins is a highly specific defect in this protein.
Another assay available to detect Scap function is the in vitro budding assay (1). Scapcontaining membranes are isolated from cells grown in the absence or presence of 25-hydroxycholesterol.
The membranes are incubated in vitro with cytosol plus GTP, which allows the formation of COPII-coated vesicles. The vesicles are separated from the membrane by centrifugation, and the Scap content of the vesicles is determined by SDS-PAGE and immunoblotting. The experiment of Fig. 7B was performed with membranes from Scap-deficient SRD-13A cells that had been cotransfected with plasmids encoding Scap (wild-type or mutant 6) and Insig-1, which is necessary for sterol regulation. In the absence of sterols, wild-type Scap was found in the vesicle fraction (lane 1), and this budding was abolished when the cells were grown with 25-hydroxycholesterol (lane 2). Mutant Scap(D451A;L452A) was not found in the vesicle fraction either in the presence or absence of 25-hydroxycholesterol (lanes 3-4) .
We also transfected the SRD-13A cells with a plasmid encoding a truncated version of Scap that terminates at residue 767, eliminating the WD repeat region (see Fig. 4 ). The wild-type version of this truncated protein budded into the vesicle fraction (Fig. 7B, lane 5) , and this budding was reduced when the cells were grown with 25-hydroxycholesterol (lane 6). When Scap(1-767) contained the substitutions corresponding to mutant 6, the vesicle budding was markedly reduced (lanes 7 and 8) .
DISCUSSION
Elegant genetic and biochemical studies in yeast and mammalian cells have revealed a cascade of protein binding reactions that leads to the sorting of selected ER membrane proteins into COPII coated vesicles that move to the Golgi complex (reviewed in 6, 20, 21). However, there is little insight into the mechanism by which this sorting might be regulated by small molecules. In the current studies, we adapted previously described protocols so as to establish an in vitro system in which this regulation can be studied.
Using the Scap/SREBP transport process as a model, we show that addition of 25-hydroxycholesterol to isolated membranes in vitro blocks the Sar1-dependent binding of the Sec23/24 complex to Scap. This block depends on the presence of the Insig anchor proteins in the ER membranes. We further show that binding of Sec23/24 to Scap requires a conserved hexapeptide sequence, MELADL, in the cytoplasmic loop between the sixth and seventh transmembrane helices of Scap.
The mechanism by which Insigs permit sterols to block Sec23/24 binding to Scap remains to be determined. Previous studies have shown that cholesterol binds directly to Scap (22) and alters its conformation (23) , thereby causing Scap to bind to Insigs. 25-Hydroxycholesterol also causes Scap to bind to Insigs, but it does not bind directly to Scap (22) , nor does it cause a conformational change (23) . We believe that 25-hydroxycholesterol acts indirectly through another ER protein that is yet to be characterized. When Scap binds to Insigs, the COPII proteins no longer bind to Scap. Loop 6 does not participate directly in the Scap-Insig interaction since truncated Scap lacking loop 6 still binds to Insig in a steroldependent fashion (Fig. 5A) . However, the bound Insig may somehow occlude the hexapeptide in loop 6, making it inaccessible to Sec23/24. Other more complex scenarios remain to be excluded, including the participation of other ER proteins in this regulatory response.
The general requirements for Sec23/24 binding to Scap appear to follow the model established for other ER cargo proteins. As found with other proteins (24, 25) , we found that Sar1-GTP forms a stable membrane-bound complex with Sec23/24. As expected from its general role in transport of many proteins, the Sar1-Sec23/24 complex forms independently of its interaction with Scap (see Fig. 1, lane 4) . In sterol-depleted membranes this Sar1-Sec23/24 complex binds to Scap. As with other proteins destined for COPII coated vesicles (26), this binding appears to be terminated when Sar1 hydrolyzes its bound GTP to GDP.
In previous examples of these interactions, Sec24 has been shown to be the component that binds directly to the cargo protein (6, 20, 24) . We have no reason to believe that this specificity is different when Scap is the cargo. The only difference in the current case is that Scap binding to Sec23/24 is prevented when cholesterol causes Scap to bind to Insig. We do not know whether Sar1-GTP is involved directly in binding to Scap, or whether its role is simply to attract Sec23/24 to the membrane.
The precise role of the MELADL hexapeptide remains to be elucidated. The simplest hypothesis is that Sec23/24 binds to this sequence. A variety of apparently unrelated sequences on cargo proteins have been shown to be binding sites for the Sec23/24 complex (for review, see (20, 27) ). They are all cytoplasmically disposed, as is the MELADL hexapeptide. Most of these export signals contain two acidic amino acids, as in MELADL. Others contain two hydrophobic residues like the two leucines in MELADL. Recent studies indicate that Sec24 has at least two independent binding sites for cargo proteins (28). One of these binds the sequence LASLE in the yeast cargo protein Bet1p. None of the previously described sequences precisely matches the MELADL sequence in Scap. Initial survey studies with point mutations suggest that both the di-acidic and the di-hydrophobic amino acids of the MELADL sequence may be required for export of Scap (see Fig. 7 ). More detailed studies will be necessary to determine the precise elements of the MELADL sequence that are responsible for sterol-regulated Sec23/24 binding and incorporation into COPII vesicles. Twelve h after transfection, the cells were switched to sterol-depleting medium containing 1% hydroxypropyl-β-cyclodextrin. After incubation for 1 h at 37°C, the cells were refed with steroldepleting medium either in the absence or presence of 1 µg/ml 25-hydroxycholesterol (25-HC). After 3 h at 37°C, the cells were harvested, and the microsomal membranes were assayed for Scap binding to COPII proteins using the GST-Sar1 pulldown assay (see "Experimental Procedures") with 10 µg recombinant wild type GST-Sar1 (lanes 1-4) or mutant GST-Sar1(H79G) (lanes 5-8) in the presence or absence of 0.5 mM GTP or 0.5 mM GMP-PNP as indicated. The resulting supernatant (S) and pellet (P) fractions were subjected to SDS-PAGE and immunoblot analysis with anti-GST antibody (anti-Sar1), anti-Flag antibody (anti-Sec23), and IgG-R139 (anti-Scap). Supernatant fraction represents 5% of pellet fraction. Filters were exposed to film for 5-60 s. A and B, 12 h after transfection, the cells were switched to sterol-depleting medium containing 1% hydroxypropyl-β-cyclodextrin. After incubation for 1 h at 37°C, the cells were refed with sterol-depleting medium in the presence of the indicated amount of 25-hydroxycholesterol (25-HC). After 3 h at 37°C, the cells were harvested, and the microsomal membranes were assayed for Scap binding to COPII proteins. Microsomal membranes (150 µg) were incubated with 10 µg recombinant Flag-Sec23/24 heterodimeric complex and 10 µg recombinant mutant GST-Sar1(H79G) in the presence of 0.5 mM GTP. After incubation for 15 min at 28°C, the microsomal membranes were pelleted by centrifugation, solubilized with detergent, and incubated with Glutathione-Sepharose beads. The resulting supernatant (S) and pellet (P) fractions were subjected to SDS-PAGE and immunoblot analysis with IgG-R139 (anti-Scap) and IgG-9E10 (anti-Insig-1) as indicated. Supernatant fraction represents 5% of pellet fraction. Filters were exposed to film for 60 s (top gels) and 5 s (bottom gels).
Fig. 3. In vitro addition of sterols inhibits COPII proteins binding to Scap in membrane vesicles.
On day 0, Scap-deficient SRD-13A cells were set up for experiments as described under "Experimental Procedures." On day 2, cells were transfected with 0.4 µg of pCMV-Scap, 2 µg of pTK-SREBP-2, and 0.5 µg of pCMV-VSVG-T7 (temperature sensitive ts045) in the absence (lanes 1-6) or presence (lanes 7-12) of 0.6 µg pCMV-Insig-1-Myc. Twelve h after transfection, the cells were treated with 1% hydroxypropyl-β-cyclodextrin for 1 h as described in Fig. 1 . The cells were then switched to steroldepleting medium and incubated for 3 h at 39.5°C. The cells were then harvested for preparation of microsomal membranes. Aliquots of the membranes (80 µg) were incubated in a final volume of 0.5 ml of buffer A containing the indicated concentration of the indicated sterols added in either 2 µl of ethanol (lanes 1-4 and 7-10) or 1 µl of methyl-β-cyclodextrin (lanes 5, 6 and 11, 12) . After incubation on a rotating platform for 15 min at room temperature, the reaction mixture was centrifuged at 16,000g for 10 min, and the pellet fraction was resuspended in buffer A and assayed for Scap binding to COPII proteins as described in Fig. 2A . After incubation with Glutathione-Sepharose beads, the pellet (P) and supernatant (S) fractions were subjected to SDS-PAGE and immunoblotted with IgG-R139 (anti-Scap) and IgG-T7 (anti-VSV-G). Supernatant fraction represents 5% of pellet fraction. Filters were exposed to film for 90 s (top gel) and 60 s (bottom gel). 8) . Twelve h after transfection, cells were treated with hydroxypropyl-β-cyclodextrin for 1 h as described in Fig. 1 . The cells were then switched to sterol-depleting medium and incubated for 3.5 h at 37°C. The cells were then harvested for cell fractionation as previously described (8), after which aliquots of the membrane (10 µg) and nuclear extract (35 µg) factions were subjected to SDS-PAGE and immunoblotted with anti-HSV-IgG (anti-SREBP-2) and IgG-R139 (anti-Scap). A-C, filters were exposed to film for 5-60 s. H486A;T487A;T489A; mutant 31, L504A;V506A; and mutant 32, R505A;I507A. Two mutants not shown (L498A;L500A and R473A) were expressed at low levels after transfection and were excluded from analysis. B and C, on day 0, Scap-deficient SRD-13A cells were set up for experiments as described under "Experimental Procedures." B, SREBP-2 cleavage. On day 2, cells were transfected with 2.5 µg of pTK-SREBP-2 and 0.2 µg of pCMV-Scap (wild-type or mutants 1-35 as shown in (A)). Twelve h after transfection, cells were treated with 1% hydroxypropyl-β-cyclodextrin for 1 h. The cells were then switched to sterol-depleting medium. After incubation for 3.5 h at 37°C, cells were fractionated and subjected to immunoblot analysis. C, Sar1 pulldown. On day 2, cells were transfected and treated as described in (B). Cells were harvested for assay of Scap binding to COPII proteins as described in Fig.  2A . Detergent-solubilized protein complexes were isolated by Glutathione-Sepharose beads, and the resulting pellet (P) and supernatant (S) fractions were subjected to SDS-PAGE and immunoblotted with IgG-R139 (anti-Scap). B and C, filters were exposed to film for 5-120s. 
